Highlights
About
New Chemical Entities for Insomnia and Alzheimer's Disease
Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support. Its products are aimed at addressing insomnia, problems related to the central nervous system, and neurodegenerative diseases. The company's first approved drug is Circadin, a timed-release melatonin for insomnia. Circadin is commercially available in Europe, the AsiaPacific region, and the Middle East. The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for Slenyto, a pediatric prolonged-release melatonin-coated tablet formulation for the treatment of children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome who suffer from insomnia.
Identity
| Name | Neurim Pharmaceuticals |
|---|---|
| Slug | neurim-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | neurim-pharmaceuticals |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7ys5oJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | HaBarzel Street 27, Tel Aviv, Israel |
Web & social
| Website | https://neurim.com |
|---|---|
| https://www.linkedin.com/company/1268772 |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}